Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Suplementos nutricionales para pacientes en tratamiento para la leishmaniasis visceral activa

Información

DOI:
https://doi.org/10.1002/14651858.CD012261.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 26 marzo 2018see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Enfermedades infecciosas

Clasificada:
  1. Actualizada

    No new studies identified with search

    No studies were identified for inclusion in the last search (12 Sep, 2017)

    Evaluada: 8 May 2019

Copyright:
  1. Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Estefanía Custodioa

    Correspondencia a: European Commission, Joint Research Centre (JRC), Ispra, Italy

    [email protected]

    National Centre of Tropical Medicine, Instituto de Salud Carlos III (ISCIII), Madrid, Spain

    Both authors contributed equally to this work

  • Jesús López‐Alcaldea

    Faculty of Medicine, Universidad Francisco de Vitoria (UFV) Madrid, Madrid, Spain

    Clinical Biostatistics Unit, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

    Both authors contributed equally to this work

  • Mercè Herrero

    Department of Neglected Tropical Diseases, World Health Organization (WHO), Geneva, Switzerland

  • Carmen Bouza

    Healthcare Technology Assessment Agency, Instituto de Salud Carlos III (ISCIII), Madrid, Spain

  • Carolina Jimenez

    Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

  • Stefan Storcksdieck genannt Bonsmann

    European Commission, Joint Research Centre (JRC), Ispra, Italy

  • Theodora Mouratidou

    Department of Physiatry and Nursing, University of Zaragoza, Zaragoza, Spain

  • Teresa López‐Cuadrado

    National Centre for Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain

  • Agustin Benito

    National Centre of Tropical Medicine, Instituto de Salud Carlos III (ISCIII), Madrid, Spain

  • Jorge Alvar

    Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

Contributions of authors

Tasks

Authors

Protocol development

EC, JLA, MH, CB, CJ, TLC, AB, JA

Guarantor

EC

Contact person

EC

Piloted the selection stage

EC, JLA, JA

Screened titles and abstracts and assessed full texts

EC, JLA, MH, CJ, SSgB, JA

Assessed conferences

EC, CJ, MH, SSgB, TM, JA

Requested information to researchers and companies

EC, MH, TM

Designed the data extraction form

EC, JLA

Wrote the background

EC, JA

Wrote the methodological sections of the review

EC, JLA, MH, CB, TLC

Wrote the results, discussion and conclusions sections

EC, JLA, JA

Prepared the flow‐chart

JLA

Prepared ‘Summary of findings' tables

JLA

Made an intellectual contribution and provided the clinical perspective

EC, JLA, MH, CB, CJ, SSgB, TM, TLC, AB, JA

Edited the review

EC, JLA, MH, CB, CJ, SSgB, TM, TLC, AB, JA

Assessed MECIR standards

JLA

Approved final version of the protocol prior to submission

EC, JLA, MH, CB, CJ, SSgB, TM, TLC, AB, JA

Abbreviations: Agustin Benito (AB); Carmen Bouza (CB); Carolina Jimenez (CJ); Estefanía Custodio (EC); Jesús López Alcalde (JLA); Jorge Alvar (JA); Mercè Herrero (MH); Stefan Storcksdieck genannt Bonsmann (SSgB); Teresa López‐Cuadrado (TLC); Theodora Mouratidou (TM).

Sources of support

Internal sources

  • Centro Nacional de Medicina Tropical, Instituto de Salud Carlos III, Spain.

  • Red de Investigación Cooperativa en Enfermedades Tropicales (RICET), Spain.

  • Liverpool School of Tropical Medicine, UK.

External sources

  • Department for International Development (DFID), UK.

    Grant: 5242

Declarations of interest

Agustin Benito has no known conflicts of interest.
Carmen Bouza has no known conflicts of interest.
Carolina Jimenez has no known conflicts of interest.
Estefanía Custodio has no known conflicts of interest.
Jesus Lopez Alcalde has no known conflicts of interest.
Jorge Alvar has no known conflicts of interest.
Merce Herrero has no known conflicts of interest.
Stefan Storcksdieck genannt Bonsmann has no known conflicts of interest.
Teresa López‐Cuadrado has no known conflicts of interest.
Theodora Mouratidou has no known conflicts of interest.

Acknowledgements

We acknowledge Raimundo Alcázar for bibliographical support, and Fabiana Alves for her contribution to the technical discussions.

The editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in here do not necessarily reflect UK government policy.

Version history

Published

Title

Stage

Authors

Version

2018 Mar 26

Nutritional supplements for patients being treated for active visceral leishmaniasis

Review

Estefanía Custodio, Jesús López‐Alcalde, Mercè Herrero, Carmen Bouza, Carolina Jimenez, Stefan Storcksdieck genannt Bonsmann, Theodora Mouratidou, Teresa López‐Cuadrado, Agustin Benito, Jorge Alvar

https://doi.org/10.1002/14651858.CD012261.pub2

2016 Jun 29

Nutritional supplements for patients being treated for active visceral leishmaniasis

Protocol

Estefanía Custodio, Mercè Herrero, Carmen Bouza, Jesús López‐Alcalde, Agustin Benito, Jorge Alvar

https://doi.org/10.1002/14651858.CD012261

Differences between protocol and review

Review information

  • Jesús López Alcalde is now an author, with equal contribution to Estefanía Custodio.

  • New authors joined the team: CJ, TLC, SSgB, and TM.

Search methods

In the review protocol, we did not plan to contact micronutrient companies.

Assessment of risk of bias in the included studies

In the protocol, we had planned to assess risk of bias in non‐randomized trials according to the Cochrane tool for non‐randomized studies (ACROBAT‐ NRSI; (Sterne 2014)). However, this tool is now called ROBINS‐I.

Keywords

MeSH

Medical Subject Headings Check Words

Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Study flow diagram
Figuras y tablas -
Figure 1

Study flow diagram

Table 1. Research recommendation

What are the effects of nutritional supplements in patients being treated for active visceral leishmaniasis (VL)?

Evidence: we found no eligible studies for this systematic review.

Elements

Proposal

Comments

Population

People being treated for VL

  • Include all relevant participant groups, such as people with HIV.

  • Large, adequately powered trial.

  • Preferably multi‐centre trial, in order to achieve adequate sample size (Laville 2017).

  • Stratify allocation according to age and basic nutritional status, to enable robust a priori subgroup analyses.

Intervention

Oral nutritional supplement

  • If only a nutrient is tested, a placebo can be easily used, and a blinded RCT can be conducted (Laville 2017).

  • The study should be planned with few interventions, to allow the effect of the micronutrient to be evaluated.

  • Provide details of all the interventions and co‐interventions undertaken, of their compliance and their acceptability (Hoffmann 2014; MRC 2008).

  • In order to disentangle the effects of the nutrient on the outcome measure, the co‐interventions must be similar in all study groups.

  • Compliance can be checked by counting pills, and possibly by assessing the nutrient concentration or related functions (Laville 2017).

Comparison

Placebo

Outcomes

Relevant outcomes for key stakeholders defined, measured, collected, and reported in an objective, reliable, accurate, and actionable way

  • To our knowledge, there is no 'core outcome set' (COS)a developed with a rigorous methodology for RCTs of nutritional supplements.

  • COS for RCTs of nutritional supplements should be developed with the method proposed in the COMET Handbook (Williamson 2017).

  • Blinding of patients, care givers and outcome assessment should be ensured with the use of placebo as a control group. The use of objective outcomes that are less susceptible to bias can also minimize the risk of detection bias (Lin 2012).

  • Relevant harms related to the use of nutrients should be specified beforehand, and should be assessed (Ioannidis 2004).

Study type

RCT

Cluster‐RCTs (RCTs that randomize groups (clusters) rather than individuals) have several advantages compared to individual‐RCTs (López‐Alcalde 2015). For example, they may be less costly and time‐consuming, as they simplify the logistics of implementation (Smith 2008); they control for confounding (Safdar 2008), and minimize treatment contaminationb between intervention and control participants (Hayes 2000); they are better for measuring the overall group effect of an intervention, and for judging effectiveness (Hayes 2000), that is, the extent to which a specific intervention, when used under ordinary circumstances, does what it is intended to do (Cochrane 2017). Moreover, they have broader generalizability. For example, cluster‐RCTs minimize the Hawthorne effect, which is the effect on the people being studied (usually positive or beneficial), of being under study (Porta 2008).

Abbreviations: COS: core outcome set; HIV: human immunodeficiency virus; RCT: randomized controlled trial; VL: visceral leishmaniasis.
aCore outcome set: agreed standardized set of outcomes that should be measured and reported in all trials for a specific clinical area (Williamson 2012).
bContamination: in a controlled trial, contamination is the inadvertent application of the intervention being evaluated to people in the control group, or the inadvertent failure to apply the intervention to people assigned to the intervention group (Cochrane 2017).

Figuras y tablas -
Table 1. Research recommendation
Summary of findings for the main comparison. Nutritional supplements versus no nutritional supplements for people who are being treated for active visceral leishmaniasis (VL)

Nutritional supplements versus no nutritional supplements for people who are being treated for active VL

Patient or population: people who are being treated for active VL
Setting: any
Intervention: nutritional supplements
Comparison: no nutritional supplements

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

Number of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with no nutritional supplements

Risk with nutritional supplements

Primary cure

No trials met the inclusion criteria. Thus, there is no data for this outcome.

(0 RCTs)

Definitive cure

No trials met the inclusion criteria. Thus, there is no data for this outcome.

(0 RCTs)

Treatment completion

No trials met the inclusion criteria. Thus, there is no data for this outcome.

(0 RCTs)

Self‐reported recovery from illness or resolution of symptoms

No trials met the inclusion criteria. Thus, there is no data for this outcome.

(0 RCTs)

Weight gain, increased skinfold thickness, or other measures of lean or total mass, or growth in children

No trials met the inclusion criteria. Thus, there is no data for this outcome.

(0 RCTs)

Adverse outcomes

No trials met the inclusion criteria. Thus, there is no data for this outcome.

(0 RCTs)

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Abbreviations: CI: confidence interval; VL: visceral leishmaniasis; RCT: randomized controlled trial; RR: risk ratio; OR: odds ratio.

Figuras y tablas -
Summary of findings for the main comparison. Nutritional supplements versus no nutritional supplements for people who are being treated for active visceral leishmaniasis (VL)